X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian stock markets open weak 
(Tue, 16 Dec 09:30 am) 
 
Barring China stock market (up 0.68%) and Taiwan stock market (up 0.23%), most of the Asian stock markets have opened the day on a weak today. The Japan stock market (down 1.88%) and Singapore stock market (down 1.64%) are leading the pack of losers. Even, the Indian share markets have opened the day on a negative note. All the sectoral indices have opened in red, with software and FMCG stocks witnessing maximum selling pressures.

The Sensex today is down by around 124 points (0.4%), while the NSE-Nifty is down by about 31 points (0.38%). The mid cap and small cap stocks too have also opened in red with BSE Mid Cap index and BSE Small Cap index down by around 0.25% each. The rupee is currently trading at Rs 62.65 to the US dollar.

As per the financial daily, the long awaited Goods and service tax (GST) is likely to be scheduled in the current session of parliament. However, there have been made some amendments after the centre agreed upon the two main demands of the states. One on petroleum products and two, compensation for revenue loss after the new indirect tax system is introduced. This is one more key reform Bill where the Centre has managed a broad consensus.

Majority of stocks in Indian pharma, have opened the day on a weak note, with Dishman Ltd and Dr Reddy's laboratories being the leading losers. Ranbaxy Laboratories has announced that the company has got regulatory approval to launch India's first NCE (New Chemical Entity), Synriam (arterolane maleate 150 mg + piperaquine phosphate 750 mg drug) in seven African countries viz. Nigeria, Uganda, Senegal, Cameroon Guinea, Kenya and Ivory Coast. The product has since been launched in Uganda and will be made available in other countries towards end of January 2015. This drug conforms to the recommendations of the World Health Organization (WHO) for using combination therapy in malaria. Further the drug has proved to be efficient in providing quick relief from most malaria-related symptoms, including fever, and has a high cure rate of over 95%. Launch of the anti-malaria drug can be a good opportunity in Africa given the high occurrence of this disease in these regions.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian stock markets open weak". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 25, 2017 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS